According to guidelines, how should HSV‑1 and HSV‑2 be treated for initial episodes, recurrent episodes, and suppressive therapy?

Treatment of HSV-1 and HSV-2: Initial, Recurrent, and Suppressive Therapy

The treatment approach for HSV does not differ between HSV-1 and HSV-2 genital infections—both types are managed with the same antiviral regimens and dosing schedules, though the clinical context (initial episode, recurrent episode, or suppressive therapy) determines the specific treatment strategy. 1

Initial Episode Treatment

For first clinical episodes of genital herpes, oral antiviral therapy is the standard approach:

Recommended Regimens for Initial Episodes:

• Acyclovir 400 mg orally three times daily for 7-10 days 2
• Acyclovir 200 mg orally five times daily for 7-10 days 2, 3
• Famciclovir 250 mg orally three times daily for 7-10 days 2
• Valacyclovir 1000 mg orally twice daily for 7-10 days 2

Treatment should continue until complete clinical resolution is attained. 2, 3 For severe disease requiring hospitalization (disseminated infection, pneumonitis, hepatitis, meningitis, or encephalitis), intravenous acyclovir 5-10 mg/kg body weight every 8 hours for 5-7 days is indicated. 2

Special Considerations for Initial Episodes:

• HIV-infected patients require longer treatment courses (5-14 days) and should not receive short-course therapy (1-3 days). 4
• Herpes proctitis requires higher dosing: acyclovir 400 mg orally five times daily for 10 days. 3

Recurrent Episode Treatment

Episodic therapy for recurrent episodes is most effective when initiated during the prodrome or within 1 day of lesion onset. 2 Patients should be provided with medication or a prescription to self-initiate treatment at the first sign of symptoms. 2

Recommended Regimens for Episodic Recurrent Infection:

• Acyclovir 400 mg orally three times daily for 5 days 2
• Acyclovir 200 mg orally five times daily for 5 days 2
• Acyclovir 800 mg orally twice daily for 5 days 2
• Famciclovir 125 mg orally twice daily for 5 days 2
• Valacyclovir 500 mg orally twice daily for 5 days 2

Important caveat: HIV-infected patients should receive 5-10 days of treatment for orolabial lesions and 5-14 days for genital lesions, as short-course therapy is ineffective in this population. 4

Suppressive Therapy

Daily suppressive therapy reduces the frequency of genital herpes recurrences by ≥75% and should be discussed with all HSV-2-infected patients, particularly those with frequent recurrences (≥6 episodes per year). 2, 3

Recommended Regimens for Daily Suppressive Therapy:

• Acyclovir 400 mg orally twice daily 2, 3
• Famciclovir 250 mg orally twice daily 2
• Valacyclovir 500 mg orally once daily 2
• Valacyclovir 1000 mg orally once daily 2

Key Points About Suppressive Therapy:

• Valacyclovir 500 mg once daily is less effective in patients with very frequent recurrences (≥10 episodes per year). 2
• Safety and efficacy have been documented for acyclovir for up to 6 years, and for valacyclovir and famciclovir for 1 year. 2
• After 1 year of continuous suppressive therapy, discontinuation should be discussed to reassess recurrence frequency, as episodes often decrease over time. 2, 3
• Suppressive therapy reduces but does not eliminate asymptomatic viral shedding and transmission risk. 2
• Suppressive therapy with valacyclovir 500 mg once daily reduced HSV-2 transmission to susceptible heterosexual partners by 50%. 4

HSV-1 vs HSV-2 Treatment Differences

Although episodic and suppressive therapy for genital HSV-1 have not been studied as comprehensively as for HSV-2, the same medication dosages and frequencies are recommended for both viral types. 1 There is no biologic rationale to expect different efficacy between HSV-1 and HSV-2 based on known biology and in vitro susceptibilities. 1

HIV-Infected Patients

HIV-infected patients require special consideration:

• Higher doses may be beneficial: acyclovir 400 mg orally three to five times daily. 2
• Famciclovir 500 mg twice daily is effective for decreasing recurrences and subclinical shedding. 2
• Lesions not resolving within 7-10 days suggest acyclovir resistance; viral culture with susceptibility testing should be obtained. 4
• For acyclovir-resistant HSV, IV foscarnet (40 mg/kg every 8 hours) is the treatment of choice. 4, 2
• Topical cidofovir, trifluridine, or imiquimod may be used for external lesions, requiring 21-28 days or longer. 4

Common Pitfalls to Avoid

• Do not use topical acyclovir—it is substantially less effective than oral therapy and does not improve systemic symptoms. 3
• Do not use short-course therapy (1-3 days) in HIV-infected patients—it is ineffective. 4
• Do not assume suppressive therapy eliminates transmission risk—counsel patients that asymptomatic shedding still occurs. 2
• Monitor renal function in patients receiving high-dose IV acyclovir and adjust dosing accordingly. 4